ATE522208T1 - Verwendung von phenylbuttersäure oder deren salze zur behandlung von juckreiz - Google Patents

Verwendung von phenylbuttersäure oder deren salze zur behandlung von juckreiz

Info

Publication number
ATE522208T1
ATE522208T1 AT07115426T AT07115426T ATE522208T1 AT E522208 T1 ATE522208 T1 AT E522208T1 AT 07115426 T AT07115426 T AT 07115426T AT 07115426 T AT07115426 T AT 07115426T AT E522208 T1 ATE522208 T1 AT E522208T1
Authority
AT
Austria
Prior art keywords
phenyl
salts
pruritus
treat itch
butteric acid
Prior art date
Application number
AT07115426T
Other languages
English (en)
Inventor
Yih-Lin Chung
Nam-Mew Pui
Wei-Wei Chang
Original Assignee
Asan Lab Company Cayman Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asan Lab Company Cayman Ltd filed Critical Asan Lab Company Cayman Ltd
Application granted granted Critical
Publication of ATE522208T1 publication Critical patent/ATE522208T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT07115426T 2007-08-31 2007-08-31 Verwendung von phenylbuttersäure oder deren salze zur behandlung von juckreiz ATE522208T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07115426A EP2033635B1 (de) 2007-08-31 2007-08-31 Verwendung von Phenylbuttersäure oder deren Salze zur Behandlung von Juckreiz

Publications (1)

Publication Number Publication Date
ATE522208T1 true ATE522208T1 (de) 2011-09-15

Family

ID=38969500

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07115426T ATE522208T1 (de) 2007-08-31 2007-08-31 Verwendung von phenylbuttersäure oder deren salze zur behandlung von juckreiz

Country Status (5)

Country Link
EP (2) EP2033635B1 (de)
AT (1) ATE522208T1 (de)
ES (1) ES2371671T3 (de)
PL (1) PL2033635T3 (de)
PT (1) PT2033635E (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2237684A2 (de) 2008-01-08 2010-10-13 Akthelia Pharmaceuticals Agonisten für antimikrobielle peptidsysteme
WO2012131069A1 (en) * 2011-03-31 2012-10-04 Proponent Biotech Gmbh Short chain fatty acids and their derivatives for use in treatment immunogenic disorders
WO2014053592A1 (en) * 2012-10-03 2014-04-10 Proponent Biotech Gmbh Esters of short chains fatty acids for use in the treatment of immunogenic disorders
US11065217B2 (en) 2017-01-27 2021-07-20 Temple University—Of the Commonwealth System of Higher Education Use of short chain fatty acids for the treatment and prevention of diseases and disorders
AU2018255269B2 (en) 2017-04-17 2023-03-09 The University Of Chicago Polymer materials for delivery of short-chain fatty acids to the intestine for applications in human health and treatment of disease
CN109589306A (zh) * 2017-09-30 2019-04-09 上海交通大学医学院附属第九人民医院 脂质体在制备用于清除蛋白结合毒素的药物制剂中的用途
KR102059027B1 (ko) * 2018-01-12 2019-12-24 주식회사 비엔에이치리서치 Hdac6 억제제를 유효성분으로 포함하는 가려움증 예방 또는 치료용 약제학적 조성물
DE102018123014A1 (de) * 2018-09-19 2020-03-19 Flexopharm Brain Gmbh & Co. Kg Mittel zur Verwendung bei der Behandlung von Patienten mit systemischen Entzündungserscheinungen und oxidativem Stress bei terminaler Niereninsuffizienz
CN109758444B (zh) * 2019-03-27 2021-08-24 中国农业科学院特产研究所 2-甲基取代脂肪酸在抗氧化方面的应用
WO2024117173A1 (ja) * 2022-11-30 2024-06-06 花王株式会社 痒みの予防又は改善剤
WO2024117172A1 (ja) * 2022-11-30 2024-06-06 花王株式会社 痒みの予防又は改善剤
US20250352498A1 (en) * 2024-04-12 2025-11-20 Aardvark Therapeutics Inc. Pharmaceutical formulations containing phenylbutyrate and methods thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4207241A (en) * 1967-01-13 1980-06-10 Syntex Corporation 2-Naphthyl acetic acid derivatives and compositions and methods thereof
EP1656935A1 (de) * 2004-11-12 2006-05-17 Cognis IP Management GmbH Verwendung von physiologisch aktiven Fettsäuren zur Behandlung von Pruritus
GB0617191D0 (en) * 2006-08-31 2006-10-11 York Pharma Plc Improvements in pharmaceutical compositions

Also Published As

Publication number Publication date
EP2033635A1 (de) 2009-03-11
PT2033635E (pt) 2011-12-15
EP2030616A1 (de) 2009-03-04
PL2033635T3 (pl) 2012-01-31
ES2371671T3 (es) 2012-01-09
EP2033635B1 (de) 2011-08-31

Similar Documents

Publication Publication Date Title
ATE522208T1 (de) Verwendung von phenylbuttersäure oder deren salze zur behandlung von juckreiz
MX2023007193A (es) Inhibidores de enpp1 y su uso para el tratamiento del cancer.
WO2009062118A3 (en) Modulation of protein trafficking
BR112012027915A2 (pt) nitro-ácidos graxos - neuroproteção e/ou inibição do declínio cognitivo
SMT201300095B (it) Uso dell'estere etilico dell'acido eicosapentaenoico per trattare l'ipertrigliceridemia
CL2015003602A1 (es) Composiciones y métodos para tratar anemia.
BR112015027282A2 (pt) fenfluramina para uso no tratamento de síndrome de dravet
BR112015029512A8 (pt) derivados de pirazolopirrolidina, seus usos, e composição e combinação farmacêuticas
BR112015019369A2 (pt) derivados de ácido bisfenil butanóico substituídos como inibidores de nep (endopeptidase neutra)
BR112015020600A2 (pt) composição farmacêutica, método para o tratamento de e/ou melhorar doenças de gordura no fígado de origem não alcoólica e uso da composição
WO2012050831A3 (en) Combination treatment for dermatological conditions
BR112015029401A8 (pt) derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas
BR112014010729A2 (pt) métodos para tratamento de ataques de gota
BR112013007343A2 (pt) métodos para tratar eritema associado com rosácea e para tratar telangiectasia associada com rosácea, e, composição tópica
WO2010107807A3 (en) Compounds for treating inflammation and pain
BRPI0703970A2 (pt) tratamento de pacientes psiquiátricos com função hepática reduzida com paliperidona
MX2013008715A (es) Uso de (s) -esmolol para controlar la irritacion venosa asociada con el tratamiento de un padecimiento cardiaco.
BR112015006063A2 (pt) compostos heteroaromáticos, processo para preparar os compostos, composições farmacêuticas, usos e método de tratamento para as dores aguda e crônica
PH12014500191A1 (en) Use of organic compound for the treatment of noonan syndrome
EA200970764A1 (ru) Способ лечения расстройств, вызванных пролиферацией клеток, с применением стимуляторов секреции гормона роста
UA112418C2 (uk) Терапевтичний болезаспокійливий засіб
CA2796412A1 (en) Method for treating scars with adapalene 0.3%
BRPI0510370A (pt) derivados de ácido fenoxi-alquil-carboxìlico no tratamento de doenças inflamatórias
PH12014502282A1 (en) Method for treating hyperuricemia in patients with gout using halofenate or halofenic acid and an anti-inflammatory agent
MX2014005400A (es) Metodos para tratar hiperucemia en pacientes con gota utilizando halofenato o acido halofenico y un segundo agente de reduccion de urato.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties